UNLABELLED: Based on small single-centre series, the risk of invasive fungal infections (IFI) has been considered small in autologous stem cell transplant (ASCT) recipients. PURPOSE: To analyse epidemiological and clinical features of (IFI) among ASCT recipients in Finland 1990-2001. PATIENTS: During the study period, 1188 adult patients received high-dose therapy supported by ASCT in six centres. Altogether, 1112 patients (94%) received blood progenitor cells. The graft was CD34+ selected in 261 patients (22%). The major diagnostic groups were non-Hodgkin's lymphoma (n = 417), multiple myeloma (n = 395), breast cancer (n = 132) and Hodgkin's lymphoma (n = 53). RESULTS: Eighteen patients (1.5%) with IFI were identified. The incidence of proven or probable invasive aspergillosis was 0.8%, followed by candidaemia with an incidence of 0.3%. The median time to the diagnosis of IFI was 35 d (6-162) from the progenitor cell infusion. In fourteen patients (78%) IFI was diagnosed during lifetime and they were treated with antifungal therapy for a median of 50 d. Nine patients (64%) were cured. CONCLUSIONS: IFI appears to be a rare event after ASCT and Aspergillus infections seem to be predominant. These epidemiological features have an impact in planning prophylactic and empirical antifungal strategies in ASCT recipients. Copyright Blackwell Munksgard 2004.
UNLABELLED: Based on small single-centre series, the risk of invasive fungal infections (IFI) has been considered small in autologous stem cell transplant (ASCT) recipients. PURPOSE: To analyse epidemiological and clinical features of (IFI) among ASCT recipients in Finland 1990-2001. PATIENTS: During the study period, 1188 adult patients received high-dose therapy supported by ASCT in six centres. Altogether, 1112 patients (94%) received blood progenitor cells. The graft was CD34+ selected in 261 patients (22%). The major diagnostic groups were non-Hodgkin's lymphoma (n = 417), multiple myeloma (n = 395), breast cancer (n = 132) and Hodgkin's lymphoma (n = 53). RESULTS: Eighteen patients (1.5%) with IFI were identified. The incidence of proven or probable invasive aspergillosis was 0.8%, followed by candidaemia with an incidence of 0.3%. The median time to the diagnosis of IFI was 35 d (6-162) from the progenitor cell infusion. In fourteen patients (78%) IFI was diagnosed during lifetime and they were treated with antifungal therapy for a median of 50 d. Nine patients (64%) were cured. CONCLUSIONS: IFI appears to be a rare event after ASCT and Aspergillus infections seem to be predominant. These epidemiological features have an impact in planning prophylactic and empirical antifungal strategies in ASCT recipients. Copyright Blackwell Munksgard 2004.
Authors: Benjamin W Teh; Jasmine C Teng; Karin Urbancic; Andrew Grigg; Simon J Harrison; Leon J Worth; Monica A Slavin; Karin A Thursky Journal: Haematologica Date: 2014-10-10 Impact factor: 9.941
Authors: Yae-Jean Kim; Ki Woong Sung; Hye Sook Hwang; Shin Han Jung; Ju Youn Kim; Eun Joo Cho; Su Jin Lim; Young Bae Choi; Hee Won Cheuh; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo Journal: Yonsei Med J Date: 2011-03 Impact factor: 2.759
Authors: L Drgona; A Khachatryan; J Stephens; C Charbonneau; M Kantecki; S Haider; R Barnes Journal: Eur J Clin Microbiol Infect Dis Date: 2013-09-12 Impact factor: 3.267
Authors: David W Denning; Kieren A Marr; Wendi M Lau; David P Facklam; Voravit Ratanatharathorn; Cornelia Becker; Andrew J Ullmann; Nita L Seibel; Patricia M Flynn; Jo-Anne H van Burik; Donald N Buell; Thomas F Patterson Journal: J Infect Date: 2006-05-06 Impact factor: 6.072